Supporting oncology professionals through education
The content on this site is intended for healthcare professionals only
The content on this site is intended for healthcare professionals only
Use of statins before or after a diagnosis of colorectal cancer was linked with a lower risk of premature death, both from cancer and from other causes, in a Cancer Medicine analysis of published studies.
The meta-analysis included 14 studies involving 130,994 patients with colorectal cancer.
Pre-diagnosis statin use was linked with a 15 percent lower risk of dying early from any cause and an 18 percent lower risk of dying from cancer.
Post-diagnosis statin use was linked with a 14 percent lower risk of all-cause death and a 21 percent lower risk of cancer-specific death.
"Considering that statins are low-costed and wildly-used agents worldwide, we believe our updated meta-analysis can provide new insights into optimising adjuvant treatment of colorectal cancer," the authors wrote.
Source: Wiley
We are an independent charity and are not backed by a large company or society. We raise every penny ourselves to improve the standards of cancer care through education. You can help us continue our work to address inequalities in cancer care by making a donation.
Any donation, however small, contributes directly towards the costs of creating and sharing free oncology education.
Together we can get better outcomes for patients by tackling global inequalities in access to the results of cancer research.
Thank you for your support.